Jerphason Ongayo Mecha
Has grant
Biostatistician
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Enhancing Adherence and Completion of the Three-Month Isoniazid with Rifapentine (3HP) Tuberculosis Preventive Therapy Regimen Through Biomarker-Guided Adherence Counselling (ACT-TPT)
Open Date: 2025-12-01
Close Date: 2030-12-01
Grant: Close
Factors Affecting the Implementation of Short-Course Tuberculosis Preventive Therapy Regimens(3HP) among People Living with HIV (PLHIV) in Kisumu County, Kenya: A Qualitative Study
Open Date: 2024-12-01
Close Date: 2025-12-01
Grant: Close
Systems Analysis and Improvement Approach to Optimize the Tuberculosis Preventive Therapy Cascade (SAIA-TPT)
Open Date: 2023-11-01
Close Date: 2026-02-01
Grant: Close
Factors affecting uptake, adherence and outcomes of newer recommended short-regimen tuberculosis preventive therapy among people living with HIV in Kenya
Open Date: 2023-01-01
Close Date: 2024-12-01
Articles (11)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Background: The effect of maternal HIV on infant Mycobacterium tuberculosis (Mtb) infection risk is not well-characterized. Methods: Pregnant women with/without HIV and their infants were enrolled in a longitudinal cohort in Kenya. Mothers had interferon gamma-release assays (QFT-Plus) and tuberculin skin tests (TST) at enrollment in pregnancy; children underwent TST at 12 and 24 months of age. We estimated the incidence and correlates of infant TST-positivity using Cox proportional hazards regression. Results: Among 322 infants, 170 (53%) were HIV-exposed and 152 (47%) were HIV-unexposed. Median enrollment age was 6.6 weeks [interquartile range (IQR): 6.1–10.0]; most received Bacillus Calmette-Guerin (320, 99%). Thirty-nine (12%) mothers were TST-positive; 102 (32%) were QFT-Plus-positive. Among HIV-exposed infants, 154 (95%) received antiretrovirals for HIV prevention and 141 (83%) of their mothers ever received isoniazid preventive therapy (IPT). Cumulative 24-month infant Mtb infection incidence was 3.6/100 person-years (PY) [95% confidence interval (CI): 2.4–5.5/100 PY]; 5.4/100 PY in HIV-exposed infants (10%, 17/170) versus 1.7/100 PY in HIV-unexposed infants (3.3%, 5/152) [hazard ratio (HR): 3.1 (95% CI: 1.2–8.5)]. More TST conversions occurred in the first versus second year of life [5.8 vs. 2.0/100 PY; HR: 2.9 (95% CI: 1.0–10.1)]. Infant TST-positivity was associated with maternal TST-positivity [HR: 2.9 (95% CI: 1.1–7.4)], but not QFT-Plus-positivity. Among HIV-exposed children, Mtb infection incidence was similar regardless of maternal IPT. Conclusions: Mtb infection incidence (by TST) by 24 months of age was ~3-fold higher among HIV-exposed children, despite high maternal IPT uptake. Overall, more TST conversions occurred in the first 12 months compared to 12–24 months of age, similar in both HIV-exposed and HIV-unexposed children.
Year:
2023
Year:
2023
Year:
2023
Collaborators (10)
Jeremy Boss
Professor and Chair
Emory University School of Medicine
Ashenafi Cherkos
Assistant Professor
University of North Texas Health Science Center
Joy Githua
Kenya Medical Research Institute
Lilian N Njagi
Senior Clinical Research Scientist
Kenya Medical Research Institute
Thomas Hawn
Professor
University of Washington
Marianne AB van der Sande
Institute of Tropical Medicine Antwerp
David Horne
Professor
University of Washington
Nuttada Panpradist
Assistant Professor
University of Texas at Austin
Grace John-Stewart
Professor
University of Washington
Sylvia M. LaCourse
University of Washington
Make your next move.
Prepare your application
Review drafts before you send them.